nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP2B6—Thiotepa—urinary bladder cancer	0.19	0.426	CbGbCtD
Mianserin—CYP3A4—Thiotepa—urinary bladder cancer	0.0584	0.131	CbGbCtD
Mianserin—CYP2B6—Cisplatin—urinary bladder cancer	0.0525	0.118	CbGbCtD
Mianserin—CYP1A2—Fluorouracil—urinary bladder cancer	0.0362	0.0812	CbGbCtD
Mianserin—CYP2B6—Doxorubicin—urinary bladder cancer	0.0352	0.0788	CbGbCtD
Mianserin—HTR7—vas deferens—urinary bladder cancer	0.034	0.244	CbGeAlD
Mianserin—CYP1A2—Etoposide—urinary bladder cancer	0.0302	0.0677	CbGbCtD
Mianserin—CYP2D6—Doxorubicin—urinary bladder cancer	0.017	0.0381	CbGbCtD
Mianserin—CYP3A4—Etoposide—urinary bladder cancer	0.0158	0.0355	CbGbCtD
Mianserin—CYP3A4—Doxorubicin—urinary bladder cancer	0.0108	0.0242	CbGbCtD
Mianserin—CYP1A2—urine—urinary bladder cancer	0.00675	0.0484	CbGeAlD
Mianserin—OPRK1—prostate gland—urinary bladder cancer	0.00605	0.0434	CbGeAlD
Mianserin—HTR2A—urine—urinary bladder cancer	0.00528	0.0379	CbGeAlD
Mianserin—CYP3A4—urine—urinary bladder cancer	0.00489	0.0351	CbGeAlD
Mianserin—CYP2D6—urine—urinary bladder cancer	0.00481	0.0345	CbGeAlD
Mianserin—OPRK1—female reproductive system—urinary bladder cancer	0.0033	0.0237	CbGeAlD
Mianserin—ADRA2C—prostate gland—urinary bladder cancer	0.00279	0.02	CbGeAlD
Mianserin—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00251	0.018	CbGeAlD
Mianserin—ADRA2C—seminal vesicle—urinary bladder cancer	0.00236	0.017	CbGeAlD
Mianserin—HRH1—prostate gland—urinary bladder cancer	0.00227	0.0163	CbGeAlD
Mianserin—HTR7—epithelium—urinary bladder cancer	0.00223	0.016	CbGeAlD
Mianserin—ADRA2A—prostate gland—urinary bladder cancer	0.00223	0.016	CbGeAlD
Mianserin—HTR1A—renal system—urinary bladder cancer	0.00217	0.0156	CbGeAlD
Mianserin—HTR7—smooth muscle tissue—urinary bladder cancer	0.00215	0.0154	CbGeAlD
Mianserin—HTR1D—female reproductive system—urinary bladder cancer	0.00208	0.0149	CbGeAlD
Mianserin—HTR7—renal system—urinary bladder cancer	0.00207	0.0149	CbGeAlD
Mianserin—HTR2C—female reproductive system—urinary bladder cancer	0.00206	0.0148	CbGeAlD
Mianserin—SLC6A4—female reproductive system—urinary bladder cancer	0.00195	0.014	CbGeAlD
Mianserin—HTR2B—female reproductive system—urinary bladder cancer	0.00194	0.0139	CbGeAlD
Mianserin—HRH2—lymph node—urinary bladder cancer	0.00191	0.0137	CbGeAlD
Mianserin—ADRA2C—renal system—urinary bladder cancer	0.0019	0.0137	CbGeAlD
Mianserin—ADRA2A—seminal vesicle—urinary bladder cancer	0.00188	0.0135	CbGeAlD
Mianserin—ADRA2C—urethra—urinary bladder cancer	0.00187	0.0134	CbGeAlD
Mianserin—HTR2B—vagina—urinary bladder cancer	0.00175	0.0126	CbGeAlD
Mianserin—SLC6A2—female reproductive system—urinary bladder cancer	0.00172	0.0123	CbGeAlD
Mianserin—HRH1—epithelium—urinary bladder cancer	0.00167	0.012	CbGeAlD
Mianserin—HTR7—female reproductive system—urinary bladder cancer	0.00166	0.0119	CbGeAlD
Mianserin—CYP1A2—renal system—urinary bladder cancer	0.00165	0.0119	CbGeAlD
Mianserin—HRH1—smooth muscle tissue—urinary bladder cancer	0.00161	0.0115	CbGeAlD
Mianserin—CYP2B6—renal system—urinary bladder cancer	0.00158	0.0114	CbGeAlD
Mianserin—HRH1—urethra—urinary bladder cancer	0.00152	0.0109	CbGeAlD
Mianserin—ADRA2A—urethra—urinary bladder cancer	0.00149	0.0107	CbGeAlD
Mianserin—HTR2A—epithelium—urinary bladder cancer	0.00139	0.00999	CbGeAlD
Mianserin—ADRA2C—vagina—urinary bladder cancer	0.00138	0.00989	CbGeAlD
Mianserin—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00134	0.00963	CbGeAlD
Mianserin—HTR2A—renal system—urinary bladder cancer	0.00129	0.00927	CbGeAlD
Mianserin—CYP2B6—female reproductive system—urinary bladder cancer	0.00127	0.0091	CbGeAlD
Mianserin—HRH1—female reproductive system—urinary bladder cancer	0.00124	0.00889	CbGeAlD
Mianserin—ADRA2A—female reproductive system—urinary bladder cancer	0.00122	0.00873	CbGeAlD
Mianserin—CYP3A4—renal system—urinary bladder cancer	0.0012	0.00858	CbGeAlD
Mianserin—CYP2D6—renal system—urinary bladder cancer	0.00118	0.00844	CbGeAlD
Mianserin—CYP2B6—vagina—urinary bladder cancer	0.00115	0.00823	CbGeAlD
Mianserin—HTR2B—lymph node—urinary bladder cancer	0.00113	0.00813	CbGeAlD
Mianserin—HRH1—vagina—urinary bladder cancer	0.00112	0.00804	CbGeAlD
Mianserin—ADRA2A—vagina—urinary bladder cancer	0.0011	0.00789	CbGeAlD
Mianserin—HTR2A—female reproductive system—urinary bladder cancer	0.00103	0.00742	CbGeAlD
Mianserin—SLC6A2—lymph node—urinary bladder cancer	0.00101	0.00722	CbGeAlD
Mianserin—Cardiac disorder—Etoposide—urinary bladder cancer	0.000971	0.0032	CcSEcCtD
Mianserin—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00097	0.00319	CcSEcCtD
Mianserin—Anaemia—Fluorouracil—urinary bladder cancer	0.000969	0.00319	CcSEcCtD
Mianserin—CYP3A4—female reproductive system—urinary bladder cancer	0.000957	0.00687	CbGeAlD
Mianserin—Leukopenia—Gemcitabine—urinary bladder cancer	0.000955	0.00314	CcSEcCtD
Mianserin—Angiopathy—Etoposide—urinary bladder cancer	0.000949	0.00313	CcSEcCtD
Mianserin—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000943	0.0031	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000943	0.0031	CcSEcCtD
Mianserin—CYP2D6—female reproductive system—urinary bladder cancer	0.000942	0.00676	CbGeAlD
Mianserin—Leukopenia—Fluorouracil—urinary bladder cancer	0.000939	0.00309	CcSEcCtD
Mianserin—HTR2A—vagina—urinary bladder cancer	0.000935	0.00671	CbGeAlD
Mianserin—Tremor—Cisplatin—urinary bladder cancer	0.000931	0.00307	CcSEcCtD
Mianserin—Paraesthesia—Thiotepa—urinary bladder cancer	0.000929	0.00306	CcSEcCtD
Mianserin—Lethargy—Methotrexate—urinary bladder cancer	0.000924	0.00304	CcSEcCtD
Mianserin—Hypertension—Gemcitabine—urinary bladder cancer	0.000921	0.00303	CcSEcCtD
Mianserin—Somnolence—Thiotepa—urinary bladder cancer	0.00092	0.00303	CcSEcCtD
Mianserin—Anaemia—Cisplatin—urinary bladder cancer	0.000919	0.00303	CcSEcCtD
Mianserin—Convulsion—Fluorouracil—urinary bladder cancer	0.000909	0.00299	CcSEcCtD
Mianserin—Arthralgia—Gemcitabine—urinary bladder cancer	0.000908	0.00299	CcSEcCtD
Mianserin—Myalgia—Gemcitabine—urinary bladder cancer	0.000908	0.00299	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000902	0.00297	CcSEcCtD
Mianserin—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000897	0.00296	CcSEcCtD
Mianserin—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000893	0.00294	CcSEcCtD
Mianserin—Myalgia—Fluorouracil—urinary bladder cancer	0.000893	0.00294	CcSEcCtD
Mianserin—Fatigue—Thiotepa—urinary bladder cancer	0.000892	0.00294	CcSEcCtD
Mianserin—ADRA2C—lymph node—urinary bladder cancer	0.000892	0.0064	CbGeAlD
Mianserin—Leukopenia—Cisplatin—urinary bladder cancer	0.00089	0.00293	CcSEcCtD
Mianserin—Constipation—Thiotepa—urinary bladder cancer	0.000885	0.00291	CcSEcCtD
Mianserin—Oedema—Gemcitabine—urinary bladder cancer	0.00087	0.00287	CcSEcCtD
Mianserin—Cardiac failure—Epirubicin—urinary bladder cancer	0.000869	0.00286	CcSEcCtD
Mianserin—Lethargy—Epirubicin—urinary bladder cancer	0.000865	0.00285	CcSEcCtD
Mianserin—Confusional state—Fluorouracil—urinary bladder cancer	0.000863	0.00284	CcSEcCtD
Mianserin—Convulsion—Cisplatin—urinary bladder cancer	0.000861	0.00284	CcSEcCtD
Mianserin—Oedema—Fluorouracil—urinary bladder cancer	0.000856	0.00282	CcSEcCtD
Mianserin—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000854	0.00281	CcSEcCtD
Mianserin—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000853	0.00281	CcSEcCtD
Mianserin—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000852	0.00281	CcSEcCtD
Mianserin—Diplopia—Epirubicin—urinary bladder cancer	0.000848	0.00279	CcSEcCtD
Mianserin—Myalgia—Cisplatin—urinary bladder cancer	0.000846	0.00279	CcSEcCtD
Mianserin—Skin disorder—Gemcitabine—urinary bladder cancer	0.000845	0.00278	CcSEcCtD
Mianserin—Anaemia—Etoposide—urinary bladder cancer	0.000842	0.00277	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00084	0.00277	CcSEcCtD
Mianserin—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000839	0.00276	CcSEcCtD
Mianserin—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000838	0.00276	CcSEcCtD
Mianserin—Tachycardia—Fluorouracil—urinary bladder cancer	0.000835	0.00275	CcSEcCtD
Mianserin—Breast disorder—Methotrexate—urinary bladder cancer	0.000819	0.0027	CcSEcCtD
Mianserin—Vertigo—Etoposide—urinary bladder cancer	0.000818	0.00269	CcSEcCtD
Mianserin—Leukopenia—Etoposide—urinary bladder cancer	0.000815	0.00268	CcSEcCtD
Mianserin—Hypotension—Gemcitabine—urinary bladder cancer	0.000813	0.00268	CcSEcCtD
Mianserin—Oedema—Cisplatin—urinary bladder cancer	0.000811	0.00267	CcSEcCtD
Mianserin—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000806	0.00265	CcSEcCtD
Mianserin—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000804	0.00265	CcSEcCtD
Mianserin—Loss of consciousness—Etoposide—urinary bladder cancer	0.0008	0.00264	CcSEcCtD
Mianserin—Lethargy—Doxorubicin—urinary bladder cancer	0.0008	0.00264	CcSEcCtD
Mianserin—Hypotension—Fluorouracil—urinary bladder cancer	0.0008	0.00263	CcSEcCtD
Mianserin—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000796	0.00262	CcSEcCtD
Mianserin—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000794	0.00262	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000793	0.00261	CcSEcCtD
Mianserin—Tachycardia—Cisplatin—urinary bladder cancer	0.000792	0.00261	CcSEcCtD
Mianserin—Convulsion—Etoposide—urinary bladder cancer	0.000789	0.0026	CcSEcCtD
Mianserin—Skin disorder—Cisplatin—urinary bladder cancer	0.000788	0.00259	CcSEcCtD
Mianserin—Hypertension—Etoposide—urinary bladder cancer	0.000786	0.00259	CcSEcCtD
Mianserin—Diplopia—Doxorubicin—urinary bladder cancer	0.000784	0.00258	CcSEcCtD
Mianserin—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000782	0.00257	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00078	0.00257	CcSEcCtD
Mianserin—Somnolence—Gemcitabine—urinary bladder cancer	0.000774	0.00255	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00077	0.00254	CcSEcCtD
Mianserin—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000768	0.00253	CcSEcCtD
Mianserin—Breast disorder—Epirubicin—urinary bladder cancer	0.000766	0.00252	CcSEcCtD
Mianserin—Somnolence—Fluorouracil—urinary bladder cancer	0.000761	0.00251	CcSEcCtD
Mianserin—Hypotension—Cisplatin—urinary bladder cancer	0.000758	0.0025	CcSEcCtD
Mianserin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000751	0.00247	CcSEcCtD
Mianserin—Fatigue—Gemcitabine—urinary bladder cancer	0.00075	0.00247	CcSEcCtD
Mianserin—Confusional state—Etoposide—urinary bladder cancer	0.000749	0.00247	CcSEcCtD
Mianserin—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000746	0.00246	CcSEcCtD
Mianserin—Constipation—Gemcitabine—urinary bladder cancer	0.000744	0.00245	CcSEcCtD
Mianserin—Pancytopenia—Methotrexate—urinary bladder cancer	0.000743	0.00245	CcSEcCtD
Mianserin—Asthenia—Thiotepa—urinary bladder cancer	0.000742	0.00244	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000739	0.00243	CcSEcCtD
Mianserin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000739	0.00243	CcSEcCtD
Mianserin—Neutropenia—Methotrexate—urinary bladder cancer	0.000732	0.00241	CcSEcCtD
Mianserin—Pruritus—Thiotepa—urinary bladder cancer	0.000732	0.00241	CcSEcCtD
Mianserin—Paraesthesia—Cisplatin—urinary bladder cancer	0.000728	0.0024	CcSEcCtD
Mianserin—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000728	0.0024	CcSEcCtD
Mianserin—Tachycardia—Etoposide—urinary bladder cancer	0.000725	0.00239	CcSEcCtD
Mianserin—HRH1—lymph node—urinary bladder cancer	0.000724	0.0052	CbGeAlD
Mianserin—Skin disorder—Etoposide—urinary bladder cancer	0.000722	0.00238	CcSEcCtD
Mianserin—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000721	0.00237	CcSEcCtD
Mianserin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000717	0.00236	CcSEcCtD
Mianserin—ADRA2A—lymph node—urinary bladder cancer	0.000711	0.00511	CbGeAlD
Mianserin—Breast disorder—Doxorubicin—urinary bladder cancer	0.000709	0.00233	CcSEcCtD
Mianserin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000705	0.00232	CcSEcCtD
Mianserin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.0007	0.00231	CcSEcCtD
Mianserin—Drowsiness—Methotrexate—urinary bladder cancer	0.000698	0.0023	CcSEcCtD
Mianserin—Pancytopenia—Epirubicin—urinary bladder cancer	0.000696	0.00229	CcSEcCtD
Mianserin—Hypotension—Etoposide—urinary bladder cancer	0.000695	0.00229	CcSEcCtD
Mianserin—Neutropenia—Epirubicin—urinary bladder cancer	0.000685	0.00226	CcSEcCtD
Mianserin—Dizziness—Thiotepa—urinary bladder cancer	0.000684	0.00225	CcSEcCtD
Mianserin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000669	0.0022	CcSEcCtD
Mianserin—Paraesthesia—Etoposide—urinary bladder cancer	0.000667	0.0022	CcSEcCtD
Mianserin—Weight increased—Epirubicin—urinary bladder cancer	0.000667	0.0022	CcSEcCtD
Mianserin—Somnolence—Etoposide—urinary bladder cancer	0.000661	0.00218	CcSEcCtD
Mianserin—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00066	0.00217	CcSEcCtD
Mianserin—Drowsiness—Epirubicin—urinary bladder cancer	0.000653	0.00215	CcSEcCtD
Mianserin—Rash—Thiotepa—urinary bladder cancer	0.000652	0.00215	CcSEcCtD
Mianserin—Dermatitis—Thiotepa—urinary bladder cancer	0.000652	0.00215	CcSEcCtD
Mianserin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000651	0.00214	CcSEcCtD
Mianserin—Headache—Thiotepa—urinary bladder cancer	0.000648	0.00213	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000644	0.00212	CcSEcCtD
Mianserin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000642	0.00211	CcSEcCtD
Mianserin—Fatigue—Etoposide—urinary bladder cancer	0.000641	0.00211	CcSEcCtD
Mianserin—Jaundice—Epirubicin—urinary bladder cancer	0.000637	0.0021	CcSEcCtD
Mianserin—Constipation—Etoposide—urinary bladder cancer	0.000636	0.00209	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—urinary bladder cancer	0.000634	0.00209	CcSEcCtD
Mianserin—Hepatitis—Methotrexate—urinary bladder cancer	0.000627	0.00206	CcSEcCtD
Mianserin—Asthenia—Gemcitabine—urinary bladder cancer	0.000624	0.00206	CcSEcCtD
Mianserin—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000618	0.00203	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—urinary bladder cancer	0.000617	0.00203	CcSEcCtD
Mianserin—Pruritus—Gemcitabine—urinary bladder cancer	0.000616	0.00203	CcSEcCtD
Mianserin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000612	0.00202	CcSEcCtD
Mianserin—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00061	0.00201	CcSEcCtD
Mianserin—Pruritus—Fluorouracil—urinary bladder cancer	0.000605	0.00199	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—urinary bladder cancer	0.000604	0.00199	CcSEcCtD
Mianserin—Bradycardia—Epirubicin—urinary bladder cancer	0.000597	0.00197	CcSEcCtD
Mianserin—Jaundice—Doxorubicin—urinary bladder cancer	0.000589	0.00194	CcSEcCtD
Mianserin—Hepatitis—Epirubicin—urinary bladder cancer	0.000586	0.00193	CcSEcCtD
Mianserin—Eye disorder—Methotrexate—urinary bladder cancer	0.000586	0.00193	CcSEcCtD
Mianserin—Tinnitus—Methotrexate—urinary bladder cancer	0.000584	0.00192	CcSEcCtD
Mianserin—Asthenia—Cisplatin—urinary bladder cancer	0.000582	0.00192	CcSEcCtD
Mianserin—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000582	0.00191	CcSEcCtD
Mianserin—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000576	0.0019	CcSEcCtD
Mianserin—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000572	0.00188	CcSEcCtD
Mianserin—Angiopathy—Methotrexate—urinary bladder cancer	0.000569	0.00187	CcSEcCtD
Mianserin—Dizziness—Fluorouracil—urinary bladder cancer	0.000566	0.00186	CcSEcCtD
Mianserin—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000565	0.00186	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000564	0.00186	CcSEcCtD
Mianserin—Bradycardia—Doxorubicin—urinary bladder cancer	0.000552	0.00182	CcSEcCtD
Mianserin—Mental disorder—Methotrexate—urinary bladder cancer	0.000549	0.00181	CcSEcCtD
Mianserin—Rash—Gemcitabine—urinary bladder cancer	0.000549	0.00181	CcSEcCtD
Mianserin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000548	0.00181	CcSEcCtD
Mianserin—Eye disorder—Epirubicin—urinary bladder cancer	0.000548	0.0018	CcSEcCtD
Mianserin—Tinnitus—Epirubicin—urinary bladder cancer	0.000547	0.0018	CcSEcCtD
Mianserin—Headache—Gemcitabine—urinary bladder cancer	0.000545	0.0018	CcSEcCtD
Mianserin—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000544	0.00179	CcSEcCtD
Mianserin—Hepatitis—Doxorubicin—urinary bladder cancer	0.000543	0.00179	CcSEcCtD
Mianserin—Rash—Fluorouracil—urinary bladder cancer	0.00054	0.00178	CcSEcCtD
Mianserin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000539	0.00178	CcSEcCtD
Mianserin—Headache—Fluorouracil—urinary bladder cancer	0.000536	0.00177	CcSEcCtD
Mianserin—Asthenia—Etoposide—urinary bladder cancer	0.000533	0.00176	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000533	0.00176	CcSEcCtD
Mianserin—Angiopathy—Epirubicin—urinary bladder cancer	0.000532	0.00175	CcSEcCtD
Mianserin—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000529	0.00174	CcSEcCtD
Mianserin—Pruritus—Etoposide—urinary bladder cancer	0.000526	0.00173	CcSEcCtD
Mianserin—Mental disorder—Epirubicin—urinary bladder cancer	0.000514	0.00169	CcSEcCtD
Mianserin—Rash—Cisplatin—urinary bladder cancer	0.000512	0.00168	CcSEcCtD
Mianserin—Dermatitis—Cisplatin—urinary bladder cancer	0.000511	0.00168	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000507	0.00167	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—urinary bladder cancer	0.000506	0.00167	CcSEcCtD
Mianserin—Anaemia—Methotrexate—urinary bladder cancer	0.000504	0.00166	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000504	0.00166	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000492	0.00162	CcSEcCtD
Mianserin—Dizziness—Etoposide—urinary bladder cancer	0.000491	0.00162	CcSEcCtD
Mianserin—Vertigo—Methotrexate—urinary bladder cancer	0.00049	0.00161	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000489	0.00161	CcSEcCtD
Mianserin—Leukopenia—Methotrexate—urinary bladder cancer	0.000488	0.00161	CcSEcCtD
Mianserin—Mental disorder—Doxorubicin—urinary bladder cancer	0.000475	0.00157	CcSEcCtD
Mianserin—Convulsion—Methotrexate—urinary bladder cancer	0.000473	0.00156	CcSEcCtD
Mianserin—Anaemia—Epirubicin—urinary bladder cancer	0.000472	0.00155	CcSEcCtD
Mianserin—Agitation—Epirubicin—urinary bladder cancer	0.000469	0.00154	CcSEcCtD
Mianserin—Rash—Etoposide—urinary bladder cancer	0.000469	0.00154	CcSEcCtD
Mianserin—Dermatitis—Etoposide—urinary bladder cancer	0.000468	0.00154	CcSEcCtD
Mianserin—Headache—Etoposide—urinary bladder cancer	0.000466	0.00153	CcSEcCtD
Mianserin—Arthralgia—Methotrexate—urinary bladder cancer	0.000464	0.00153	CcSEcCtD
Mianserin—Myalgia—Methotrexate—urinary bladder cancer	0.000464	0.00153	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000461	0.00152	CcSEcCtD
Mianserin—Vertigo—Epirubicin—urinary bladder cancer	0.000459	0.00151	CcSEcCtD
Mianserin—Syncope—Epirubicin—urinary bladder cancer	0.000458	0.00151	CcSEcCtD
Mianserin—Leukopenia—Epirubicin—urinary bladder cancer	0.000457	0.0015	CcSEcCtD
Mianserin—Confusional state—Methotrexate—urinary bladder cancer	0.000449	0.00148	CcSEcCtD
Mianserin—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000449	0.00148	CcSEcCtD
Mianserin—Convulsion—Epirubicin—urinary bladder cancer	0.000442	0.00146	CcSEcCtD
Mianserin—Hypertension—Epirubicin—urinary bladder cancer	0.000441	0.00145	CcSEcCtD
Mianserin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000437	0.00144	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—urinary bladder cancer	0.000437	0.00144	CcSEcCtD
Mianserin—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000436	0.00144	CcSEcCtD
Mianserin—Arthralgia—Epirubicin—urinary bladder cancer	0.000435	0.00143	CcSEcCtD
Mianserin—Myalgia—Epirubicin—urinary bladder cancer	0.000435	0.00143	CcSEcCtD
Mianserin—Agitation—Doxorubicin—urinary bladder cancer	0.000434	0.00143	CcSEcCtD
Mianserin—Skin disorder—Methotrexate—urinary bladder cancer	0.000432	0.00142	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000432	0.00142	CcSEcCtD
Mianserin—Dry mouth—Epirubicin—urinary bladder cancer	0.000425	0.0014	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—urinary bladder cancer	0.000424	0.0014	CcSEcCtD
Mianserin—Syncope—Doxorubicin—urinary bladder cancer	0.000424	0.00139	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—urinary bladder cancer	0.000423	0.00139	CcSEcCtD
Mianserin—Confusional state—Epirubicin—urinary bladder cancer	0.00042	0.00138	CcSEcCtD
Mianserin—Oedema—Epirubicin—urinary bladder cancer	0.000417	0.00137	CcSEcCtD
Mianserin—Hypotension—Methotrexate—urinary bladder cancer	0.000416	0.00137	CcSEcCtD
Mianserin—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000415	0.00137	CcSEcCtD
Mianserin—Shock—Epirubicin—urinary bladder cancer	0.00041	0.00135	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—urinary bladder cancer	0.000409	0.00135	CcSEcCtD
Mianserin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000409	0.00135	CcSEcCtD
Mianserin—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000408	0.00134	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—urinary bladder cancer	0.000408	0.00134	CcSEcCtD
Mianserin—Tachycardia—Epirubicin—urinary bladder cancer	0.000407	0.00134	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000406	0.00134	CcSEcCtD
Mianserin—Skin disorder—Epirubicin—urinary bladder cancer	0.000405	0.00133	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—urinary bladder cancer	0.000402	0.00132	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—urinary bladder cancer	0.000402	0.00132	CcSEcCtD
Mianserin—Paraesthesia—Methotrexate—urinary bladder cancer	0.0004	0.00132	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000399	0.00131	CcSEcCtD
Mianserin—Somnolence—Methotrexate—urinary bladder cancer	0.000396	0.0013	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000393	0.00129	CcSEcCtD
Mianserin—Hypotension—Epirubicin—urinary bladder cancer	0.000389	0.00128	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—urinary bladder cancer	0.000389	0.00128	CcSEcCtD
Mianserin—Oedema—Doxorubicin—urinary bladder cancer	0.000385	0.00127	CcSEcCtD
Mianserin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000384	0.00127	CcSEcCtD
Mianserin—Fatigue—Methotrexate—urinary bladder cancer	0.000384	0.00126	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00038	0.00125	CcSEcCtD
Mianserin—Shock—Doxorubicin—urinary bladder cancer	0.000379	0.00125	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000378	0.00124	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000377	0.00124	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—urinary bladder cancer	0.000376	0.00124	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000374	0.00123	CcSEcCtD
Mianserin—Paraesthesia—Epirubicin—urinary bladder cancer	0.000374	0.00123	CcSEcCtD
Mianserin—Somnolence—Epirubicin—urinary bladder cancer	0.00037	0.00122	CcSEcCtD
Mianserin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000367	0.00121	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—urinary bladder cancer	0.00036	0.00119	CcSEcCtD
Mianserin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00036	0.00118	CcSEcCtD
Mianserin—Fatigue—Epirubicin—urinary bladder cancer	0.000359	0.00118	CcSEcCtD
Mianserin—Constipation—Epirubicin—urinary bladder cancer	0.000356	0.00117	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000351	0.00116	CcSEcCtD
Mianserin—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000346	0.00114	CcSEcCtD
Mianserin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000343	0.00113	CcSEcCtD
Mianserin—Somnolence—Doxorubicin—urinary bladder cancer	0.000343	0.00113	CcSEcCtD
Mianserin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000333	0.0011	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—urinary bladder cancer	0.000332	0.00109	CcSEcCtD
Mianserin—Constipation—Doxorubicin—urinary bladder cancer	0.00033	0.00109	CcSEcCtD
Mianserin—Asthenia—Methotrexate—urinary bladder cancer	0.000319	0.00105	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000318	0.00105	CcSEcCtD
Mianserin—Pruritus—Methotrexate—urinary bladder cancer	0.000315	0.00104	CcSEcCtD
Mianserin—Asthenia—Epirubicin—urinary bladder cancer	0.000299	0.000984	CcSEcCtD
Mianserin—Pruritus—Epirubicin—urinary bladder cancer	0.000295	0.000971	CcSEcCtD
Mianserin—Dizziness—Methotrexate—urinary bladder cancer	0.000294	0.000969	CcSEcCtD
Mianserin—Rash—Methotrexate—urinary bladder cancer	0.000281	0.000924	CcSEcCtD
Mianserin—Dermatitis—Methotrexate—urinary bladder cancer	0.00028	0.000923	CcSEcCtD
Mianserin—Headache—Methotrexate—urinary bladder cancer	0.000279	0.000918	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—urinary bladder cancer	0.000277	0.000911	CcSEcCtD
Mianserin—Dizziness—Epirubicin—urinary bladder cancer	0.000276	0.000907	CcSEcCtD
Mianserin—Pruritus—Doxorubicin—urinary bladder cancer	0.000273	0.000898	CcSEcCtD
Mianserin—Rash—Epirubicin—urinary bladder cancer	0.000263	0.000865	CcSEcCtD
Mianserin—Dermatitis—Epirubicin—urinary bladder cancer	0.000262	0.000864	CcSEcCtD
Mianserin—Headache—Epirubicin—urinary bladder cancer	0.000261	0.000859	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—urinary bladder cancer	0.000255	0.000839	CcSEcCtD
Mianserin—Rash—Doxorubicin—urinary bladder cancer	0.000243	0.0008	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000243	0.0008	CcSEcCtD
Mianserin—Headache—Doxorubicin—urinary bladder cancer	0.000241	0.000795	CcSEcCtD
Mianserin—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.41e-05	0.000127	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.41e-05	0.000127	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—EP300—urinary bladder cancer	1.4e-05	0.000127	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—EP300—urinary bladder cancer	1.4e-05	0.000127	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.4e-05	0.000127	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.39e-05	0.000126	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	1.39e-05	0.000126	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	1.39e-05	0.000126	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—CXCL8—urinary bladder cancer	1.39e-05	0.000126	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	1.38e-05	0.000125	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—HRAS—urinary bladder cancer	1.38e-05	0.000125	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.38e-05	0.000125	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.37e-05	0.000124	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.37e-05	0.000124	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.37e-05	0.000124	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.37e-05	0.000124	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—SRC—urinary bladder cancer	1.36e-05	0.000124	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—SRC—urinary bladder cancer	1.36e-05	0.000123	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.36e-05	0.000123	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.36e-05	0.000123	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	1.35e-05	0.000123	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	1.35e-05	0.000122	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.35e-05	0.000122	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.34e-05	0.000122	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	1.34e-05	0.000122	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.34e-05	0.000121	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	1.33e-05	0.000121	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL2—urinary bladder cancer	1.33e-05	0.00012	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	1.32e-05	0.00012	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.32e-05	0.00012	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.32e-05	0.000119	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.32e-05	0.000119	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.31e-05	0.000119	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—TP53—urinary bladder cancer	1.31e-05	0.000119	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.3e-05	0.000118	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.3e-05	0.000118	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.3e-05	0.000118	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	1.29e-05	0.000117	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.29e-05	0.000117	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.29e-05	0.000117	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	1.28e-05	0.000116	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.28e-05	0.000116	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.28e-05	0.000115	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.27e-05	0.000115	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.27e-05	0.000115	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PTEN—urinary bladder cancer	1.26e-05	0.000114	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	1.26e-05	0.000114	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	1.25e-05	0.000114	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.25e-05	0.000113	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—HRAS—urinary bladder cancer	1.25e-05	0.000113	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	0.000113	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	1.25e-05	0.000113	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	1.25e-05	0.000113	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	1.24e-05	0.000113	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	1.24e-05	0.000113	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	1.24e-05	0.000112	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.24e-05	0.000112	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.22e-05	0.000111	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—MYC—urinary bladder cancer	1.22e-05	0.000111	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—MYC—urinary bladder cancer	1.22e-05	0.000111	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.22e-05	0.00011	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-05	0.00011	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	1.21e-05	0.00011	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	1.21e-05	0.00011	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.21e-05	0.00011	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	0.00011	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—EP300—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.2e-05	0.000109	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.2e-05	0.000108	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	1.2e-05	0.000108	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	1.19e-05	0.000108	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	1.19e-05	0.000108	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—EP300—urinary bladder cancer	1.19e-05	0.000108	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.19e-05	0.000108	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	1.19e-05	0.000107	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.18e-05	0.000107	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.18e-05	0.000107	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	0.000106	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.17e-05	0.000106	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	1.17e-05	0.000106	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—SRC—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.16e-05	0.000105	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.15e-05	0.000104	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000104	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000104	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-05	0.000104	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	1.13e-05	0.000103	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.13e-05	0.000102	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.13e-05	0.000102	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	1.13e-05	0.000102	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.13e-05	0.000102	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	1.13e-05	0.000102	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.12e-05	0.000102	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.12e-05	0.000102	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.12e-05	0.000101	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	1.12e-05	0.000101	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	1.12e-05	0.000101	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.11e-05	0.000101	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.1e-05	9.99e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.1e-05	9.97e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.1e-05	9.96e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.1e-05	9.96e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.09e-05	9.92e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	1.09e-05	9.88e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-05	9.88e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.09e-05	9.88e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.09e-05	9.87e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.09e-05	9.86e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.09e-05	9.83e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.08e-05	9.82e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.08e-05	9.81e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	9.78e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	1.08e-05	9.74e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.06e-05	9.63e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	1.06e-05	9.6e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.06e-05	9.56e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.06e-05	9.56e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	1.05e-05	9.54e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.05e-05	9.47e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	1.05e-05	9.47e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.04e-05	9.45e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.04e-05	9.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.04e-05	9.4e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.04e-05	9.4e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.04e-05	9.39e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.03e-05	9.35e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	9.34e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.02e-05	9.27e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	1.02e-05	9.22e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.02e-05	9.2e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	9.2e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-05	9.2e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.01e-05	9.14e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	1e-05	9.1e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1e-05	9.1e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1e-05	9.09e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1e-05	9.09e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—urinary bladder cancer	1e-05	9.08e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	9.99e-06	9.05e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL2—urinary bladder cancer	9.97e-06	9.03e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	9.96e-06	9.02e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	9.9e-06	8.97e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	9.77e-06	8.85e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—EP300—urinary bladder cancer	9.76e-06	8.84e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	9.74e-06	8.82e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	9.74e-06	8.82e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	9.72e-06	8.81e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.72e-06	8.8e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.65e-06	8.74e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	9.61e-06	8.71e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	9.6e-06	8.69e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—urinary bladder cancer	9.59e-06	8.69e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	9.59e-06	8.69e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	9.59e-06	8.68e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	9.58e-06	8.68e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	9.56e-06	8.66e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	9.53e-06	8.63e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	9.51e-06	8.62e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	9.46e-06	8.57e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	9.45e-06	8.56e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	9.44e-06	8.55e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.43e-06	8.54e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.41e-06	8.52e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	9.4e-06	8.52e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	9.38e-06	8.5e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	9.37e-06	8.49e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	9.34e-06	8.46e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	9.17e-06	8.3e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	9.16e-06	8.3e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—EP300—urinary bladder cancer	9.15e-06	8.29e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EP300—urinary bladder cancer	9.11e-06	8.26e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	9.09e-06	8.24e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	9.05e-06	8.19e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	9e-06	8.15e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.97e-06	8.12e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	8.97e-06	8.12e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EP300—urinary bladder cancer	8.95e-06	8.11e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.87e-06	8.03e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.87e-06	8.03e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	8.86e-06	8.03e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SRC—urinary bladder cancer	8.86e-06	8.03e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	8.85e-06	8.01e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	8.8e-06	7.97e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	8.76e-06	7.94e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	8.75e-06	7.93e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	8.72e-06	7.9e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SRC—urinary bladder cancer	8.7e-06	7.88e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	8.66e-06	7.84e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	8.61e-06	7.79e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.58e-06	7.77e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	8.56e-06	7.75e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	8.56e-06	7.75e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—urinary bladder cancer	8.52e-06	7.72e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.49e-06	7.69e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	8.36e-06	7.57e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.34e-06	7.55e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	8.32e-06	7.53e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PPARG—urinary bladder cancer	8.23e-06	7.46e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	8.16e-06	7.39e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	8.15e-06	7.38e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	8.09e-06	7.33e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—urinary bladder cancer	7.94e-06	7.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	7.93e-06	7.19e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.91e-06	7.16e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.84e-06	7.1e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	7.82e-06	7.08e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—urinary bladder cancer	7.8e-06	7.06e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	7.77e-06	7.04e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	7.7e-06	6.97e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.65e-06	6.92e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	7.64e-06	6.92e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	7.63e-06	6.91e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	7.43e-06	6.73e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	7.39e-06	6.69e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	7.36e-06	6.67e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	7.34e-06	6.65e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	7.22e-06	6.54e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	7.21e-06	6.53e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	7.19e-06	6.51e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	7.11e-06	6.44e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	7.11e-06	6.43e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	7.07e-06	6.4e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	6.95e-06	6.3e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	6.88e-06	6.23e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.67e-06	6.04e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	6.57e-06	5.95e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—urinary bladder cancer	6.52e-06	5.91e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.48e-06	5.87e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	6.42e-06	5.81e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—urinary bladder cancer	6.4e-06	5.8e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—EP300—urinary bladder cancer	6.36e-06	5.76e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.35e-06	5.75e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	6.24e-06	5.65e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	6.14e-06	5.56e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	6.12e-06	5.55e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.1e-06	5.53e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	5.84e-06	5.29e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.65e-06	5.12e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	5.58e-06	5.06e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.39e-06	4.88e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5e-06	4.53e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.36e-06	3.95e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.16e-06	3.77e-05	CbGpPWpGaD
